The brightest way to shine is by being fully, imperfectly yourself.
Self Tests are all about you. Are you outgoing or introverted? Are you a narcissist? Does perfectionism hold you back? Find out the answers to these questions and more with Psychology Today.
Posted May 22, 2025 Reviewed by Lybi Ma
Companion diagnostics in fields like oncology are well-known, but it’s their potential impact on psychiatry that is gaining attention and has the potential to shape the future of the industry. Companion diagnostics are transforming the landscape of personalized medicine by enabling more precise and effective targeted therapies. These diagnostic tools are essential for identifying the unique genetic and molecular characteristics of individual patients, allowing healthcare providers to tailor treatments accordingly.
Companion diagnostics are tests designed to detect specific biomarkers, such as genetic mutations, protein expressions, or other molecular indicators, that predict how a patient will respond to a particular therapy. By identifying these biomarkers, healthcare providers can customize treatments, leading to better outcomes and reduced side effects.
While companion diagnostics have made significant strides in oncology and other medical fields, psychiatry has traditionally lagged in precision medicine. The complexity of mental health disorders, combined with the limited understanding of their biological underpinnings, has made it challenging to develop precise, targeted treatments. Currently, many psychiatric treatments rely on trial and error, with patients often undergoing multiple medications before finding one that works. Companion diagnostics offer the potential to change that paradigm by identifying the biological factors contributing to mental health disorders, paving the way for more personalized and effective treatments.
Novel approaches—diagnosing and treating neuropsychiatric disorders with computational approaches, including state-of-the-art artificial intelligence—are moving forward. Commercial enterprises (full disclosure, like the one I am involved with) are developing advanced machine learning algorithms that can identify individuals who have a hyperactive stress hormone axis, a subset of patients that makes up around one-third of a depressed cohort. The algorithms are highly complex, but the aims are very simple. Giving clinicians the tools to efficiently predict which individuals suffer from a misfiring stress axis will enhance diagnostic confidence, expedite treatment, and ultimately improve outcomes for some of the world’s most severely depressed patients.
In psychiatry, companion diagnostics are still in their early stages but are beginning to show promise. Mental health conditions such as depression, bipolar disorder, schizophrenia, and anxiety are thought to have complex biological and genetic components. Identifying reliable biomarkers for these conditions could lead to a new era of precision psychiatry, where treatments are based on an individual’s unique biology rather than generalized treatment guidelines.
One area where companion diagnostics is gaining traction is in the treatment of depression. Pharmacogenomic tests analyze how an individual’s genetic makeup affects their response to different medications. For example, variations in CYP450 genes, which encode enzymes involved in the metabolism of various drugs, including psychiatric medications, can affect how the body metabolizes antidepressants. By identifying these variations, clinicians can choose medications that are more likely to be effective and minimize the risk of side effects. This targeted approach not only enhances treatment efficacy but also reduces the trial-and-error process, offering patients relief faster.
The introduction of companion diagnostics into psychiatry not only holds promise for more effective treatments but also has significant psychological benefits for patients. Mental health conditions are often accompanied by feelings of helplessness and frustration, especially when treatments fail to work. Companion diagnostics can help alleviate some of this emotional burden by offering patients more certainty in their treatment plans.
The current trial-and-error approach to psychiatric treatment can be mentally and emotionally draining for patients. The time it takes to find the right medication or therapy can lead to prolonged suffering and increased anxiety, particularly for those with treatment-resistant depression or severe mood disorders. Companion diagnostics can streamline this process, giving patients and clinicians more confidence in their treatment decisions and potentially reducing the number of unsuccessful treatments.
When patients know that their treatment is based on scientific evidence tied to their individual biology, they are more likely to feel empowered and engaged in their care. This sense of control can have a positive impact on mental health, improving treatment adherence and outcomes. Additionally, the data-driven approach of companion diagnostics can enhance trust between patients and healthcare providers, which is crucial in the context of mental health treatment.
Despite the promise of companion diagnostics in psychiatry, several challenges remain. Mental health disorders are complex and multifactorial, involving genetic, environmental, and psychological components. This complexity makes it difficult to identify a single biomarker or set of biomarkers that can reliably predict treatment response across different patients.
Unlike conditions like cancer, where specific genetic mutations can be targeted, mental health disorders often involve multiple genes and pathways. This makes the discovery of reliable biomarkers for psychiatric conditions a difficult task. Ongoing research is critical to identifying robust biomarkers that can guide treatment decisions in psychiatry.
Advancements in technology are likely to drive the future of companion diagnostics in psychiatry. Next-generation sequencing and other genomic technologies are making it possible to analyze large datasets of genetic information, leading to the discovery of new biomarkers associated with psychiatric conditions. In addition, advancements in neuroimaging and machine learning are providing insights into how brain activity and structure correlate with mental health disorders.
The integration of companion diagnostics with digital health tools, such as wearable devices and mobile health apps, offers another avenue for innovation. These tools can collect real-time data on patient behavior, mood, and treatment response, providing valuable insights into how treatments are working. When combined with companion diagnostics, this data can help clinicians fine-tune treatments for optimal results.
To realize the full potential of companion diagnostics in psychiatry, collaboration between researchers, clinicians, and policymakers is essential. Researchers must continue to explore the biological mechanisms underlying mental health disorders, while clinicians must be trained in the use of companion diagnostics. Additionally, ethical guidelines and regulatory frameworks must be developed to protect patients and ensure equitable access to these technologies.
Companion diagnostics are poised to revolutionize psychiatry by offering a more personalized, data-driven approach to mental health care. By identifying biomarkers that predict treatment response, these tools can reduce the trial-and-error process, improve outcomes, and enhance the psychological well-being of patients. While challenges remain, ongoing innovations in technology and research are paving the way for precision psychiatry, promising a future where mental health treatments are as individualized as the patients they serve.
Hans Eriksson, M.D., Ph.D., has worked on clinical development programs for depression, was a consulting psychiatrist and assisting head of the psychiatric clinic at Lund University Hospital. He leads the clinical programs at HMNC Brain Health.
Get the help you need from a therapist near you–a FREE service from Psychology Today.
Psychology Today © 2025 Sussex Publishers, LLC
The brightest way to shine is by being fully, imperfectly yourself.
Self Tests are all about you. Are you outgoing or introverted? Are you a narcissist? Does perfectionism hold you back? Find out the answers to these questions and more with Psychology Today.
